Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Eledon Pharmaceuticals, Inc. (ELDN) had Return on Tangible Equity of -30.63% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-36.18M |
|
-- |
|
-- |
|
$70.58M |
|
$-70.58M |
|
$34.82M |
|
$-35.75M |
|
$-35.75M |
|
$-36.18M |
|
$-36.18M |
|
$-36.18M |
|
$-36.18M |
|
$-70.58M |
|
$-73.02M |
|
48.54M |
|
48.54M |
|
$-0.75 |
|
$-0.75 |
|
| Balance Sheet Financials | |
$143.73M |
|
-- |
|
$33.67M |
|
$177.41M |
|
$11.58M |
|
-- |
|
$47.69M |
|
$59.27M |
|
$118.14M |
|
$118.14M |
|
$118.14M |
|
59.79M |
|
| Cash Flow Statement Financials | |
$-47.27M |
|
$-70.31M |
|
$133.52M |
|
$4.61M |
|
$20.55M |
|
$15.94M |
|
$13.12M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.42 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-47.27M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-30.63% |
|
|
Return on Tangible Equity |
-30.63% |
-20.40% |
|
-30.63% |
|
$1.98 |
|
$-0.97 |
|
$-0.97 |
|